XOMA Royalty Corporation has amended its definitive agreement to acquire LAVA Therapeutics, cutting the initial cash consideration to $1.04 per share and layering in a revised contingent value right that could add up to approximately $0.23 per share, depending on post-closing liability determinations. The CVR also preserves 75% of net proceeds tied to LAVA’s partnered programs and any out-licensing or sale of unpartnered assets. The parties lowered LAVA’s minimum net-cash closing condition to $24.5 million from $31.5 million, extended the tender deadline to November 12, 2025, and set a reconvened shareholder meeting for November 7, with closing expected in the fourth quarter, subject to the tender thresholds and customary conditions.
The repricing crystallizes a clear message about where value resides in this market: acquirers will pay cash for certainty and push everything else into CVRs. For XOMA, long known for buying economic interests rather than companies, taking control of LAVA’s structure and future monetization suggests a tighter hand on the levers that unlock royalty and milestone streams. The strategic question is whether this hybrid of corporate acquisition plus CVR-heavy back-end becomes the preferred template for harvesting value from partnered pipelines without underwriting full platform risk.
The immediate stakeholders are bifurcated. LAVA shareholders face a lower upfront but retain upside linked to partnered assets with Pfizer and Johnson & Johnson, including a gamma delta T cell engager targeting EGFR in solid tumors and another targeting CD33 in hematologic malignancies. Patients and investigators should see continuity, as the core programs already sit within big pharma partnerships where trial execution, pharmacovigilance, and medical education are managed at scale. Payers are not directly impacted today, yet the trajectory of these programs matters: if bispecific gamma delta T cell engagers prove durable efficacy with acceptable safety in crowded EGFR and myeloid spaces, the eventual value narrative will hinge on differentiation versus existing IO and targeted regimens as much as on price. Competitors, particularly small-cap immuno-oncology players, will read this as further confirmation that exit valuations are being anchored to net cash and verifiable partnered milestones, not to speculative platform breadth.
Several industry currents converge here. CVRs tied to discrete regulatory or transaction events have regained prominence as financing tightens and diligence surfaces contingent liabilities that buyers will not absorb upfront. Minimum net-cash conditions are being actively renegotiated as sellers’ burn and legal exposures evolve, compressing the “cash box” premium that once buffered takeouts. Royalty aggregators are edging closer to operational influence, acquiring corporate shells to optimize timing and probability of milestone realization, while avoiding late-stage development’s capital intensity. Cross-border mechanics, including tender thresholds and shareholder approvals, reinforce the value of deal certainty tools for both sides when execution windows stretch.
What to watch next is operational cadence, not just legal milestones. Uptake of the tender will signal whether investors accept downside protection via CVRs over higher cash now. Any clarity on the liability pool will reset expectations for the incremental CVR value. Clinically, meaningful readouts or transaction events around the EGFR and CD33 programs will be the true catalysts for CVR holders and for XOMA’s thesis that control can accelerate monetization. For business development and Medical Affairs leaders across the industry, the larger question is whether this structure accelerates decision velocity around partnered pipelines—prioritizing data, real-world evidence, and BD optionality—enough to make CVR-centric acquisitions a mainstream route for extracting value from stranded innovation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
